100+ Free Albania Pharmacist Certification Exam (Provimi i Certifikimit) Practice Questions

Prepare for the Provimi i Certifikimit për Profesionistët e Shëndetësisë — Farmacist (Albanian Pharmacist Periodic Recertification Examination) exam with instant access — no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately

100+ Questions

100% Free

Loading practice questions...

Same family resources

Explore More Albania Medical and Healthcare State Licensing Exams

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Albania State Exam — Physician (Provimi i Shtetit për Profesionin e Rregulluar të Mjekut)

Practice Questions103 questions

Albania State Exam — Pharmacist (Provimi i Shtetit për Profesionin e Rregulluar të Farmacistit)

Practice Questions101 questions

Albania State Exam — Midwife (Provimi i Shtetit për Profesionin e Rregulluar të Mamisë)

Practice Questions100 questions

Albania State Exam — Physiotherapist (Provimi i Shtetit për Profesionin e Rregulluar të Fizioterapistit)

Practice Questions100 questions

Albania State Exam — Speech Therapist (Provimi i Shtetit për Profesionin e Rregulluar të Logopedit)

Practice Questions100 questions

2026 Statistics

Key Facts: Albania Pharmacist Certification Exam (Provimi i Certifikimit) Exam

Law No. 10107 & VKM No. 789

Governing Framework

Kuvendi i Shqipërisë & Këshilli i Ministrave

UFSH & ASCK

Organizing Bodies

Urdhri i Farmacistëve të Shqipërisë

Practicing Pharmacists Short of CPD Credits

Target Audience

Programi i Certifikimit për Profesionistët e Shëndetësisë

75 credits per 5-year cycle

Credit Requirement

ASCK / QKEV Certification Criteria

Faculty of Medicine, Tirana

Testing Location

UFSH Official Examination Notices

3 essay questions (Commission route) or 50 MCQs (Exam Agency route)

Official Exam Questions

Certification Exam Regulation, Articles 11 and 15

At least 50% of maximum points

Passing Score

Certification Exam Regulation, Article 16

Max 2 hours (essay) / 60 minutes (computerised)

Duration

Certification Exam Regulation, Articles 11 and 15

Law No. 105/2014

Pharmacy Practice Law

Law on Drugs and Pharmaceutical Service

Albania's catch-up certification exam for licensed pharmacists who missed the 75-credit CPD quota of their 5-year cycle, under Law No. 10107 and Council of Ministers Decision No. 789/2015. A pass needs at least 50% of the maximum points; sittings run 2 hours as a three-question essay paper before the Certification Exam Commission at the Faculty of Medicine, or 60 minutes as a 50-item computerised test at the National Exam Agency when more than 50 candidates register. Distinct from the QSHA state exam for new graduates. This 100-question bank is an English-language MCQ study aid covering clinical pharmacotherapy, pharmacovigilance, interactions and toxicology, Albanian pharmaceutical law, Good Pharmacy Practice and special populations — not an official-format simulation.

Sample Albania Pharmacist Certification Exam (Provimi i Certifikimit) Practice Questions

Try these sample questions to test your Albania Pharmacist Certification Exam (Provimi i Certifikimit) exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1According to current European Society of Cardiology (ESC) guidelines for the management of arterial hypertension, what is the recommended first-line initial pharmacological strategy for most non-frail adult hypertensive patients?

A.Initial monotherapy with a thiazide diuretic, titrating to maximum dose before adding a second agent

B.Initial dual single-pill combination therapy consisting of an ACE inhibitor or ARB plus a CCB or thiazide/thiazide-like diuretic

C.High-dose beta-blocker monotherapy combined with lifestyle modifications

D.Sequential monotherapy switching between different drug classes until blood pressure is controlled

Explanation: Current clinical practice guidelines recommend initiating treatment for most adult hypertensive patients with a two-drug combination, preferably as a single-pill fixed-dose combination. The preferred combinations pair a renin-angiotensin system (RAS) blocker (ACE inhibitor or ARB) with either a dihydropyridine calcium channel blocker (CCB) or a thiazide/thiazide-like diuretic to achieve faster blood pressure control and improve long-term adherence.

2In the pharmacological management of Heart Failure with Reduced Ejection Fraction (HFrEF, LVEF ≤40%), which four foundational drug classes comprise guideline-directed 'quadruple therapy' proven to reduce cardiovascular mortality?

A.ARNI/ACEi, Evidence-based Beta-blocker, Mineralocorticoid Receptor Antagonist (MRA), and SGLT2 inhibitor

B.Loop Diuretic, Dihydropyridine CCB, Digoxin, and Statin

C.ARB, Non-dihydropyridine CCB, Nitrate, and Hydralazine

D.ACE inhibitor, Alpha-1 blocker, Potassium-sparing diuretic, and Antiarrhythmic

Explanation: Modern guideline-directed medical therapy (GDMT) for HFrEF is built upon four foundational pillar classes initiated rapidly: an Angiotensin Receptor-Neprilysin Inhibitor (ARNI, sacubitril/valsartan) or ACE inhibitor/ARB, an evidence-based beta-blocker (bisoprolol, carvedilol, or metoprolol succinate), a mineralocorticoid receptor antagonist (spironolactone or eplerenone), and an SGLT2 inhibitor (dapagliflozin or empagliflozin).

3A 62-year-old patient with Type 2 Diabetes Mellitus and established Atherosclerotic Cardiovascular Disease (ASCVD) requires intensification of glycemic therapy. Which class of antidiabetic agents is specifically recommended due to proven cardiovascular and mortality benefits?

A.Sulfonylureas (e.g., glimepiride)

B.GLP-1 receptor agonists with proven CVD benefit (e.g., liraglutide, semaglutide, dulaglutide)

C.Thiazolidinediones (e.g., pioglitazone)

D.Meglitinides (e.g., repaglinide)

Explanation: In patients with Type 2 Diabetes and established ASCVD or high cardiovascular risk, guidelines (ADA/EASD) prioritize GLP-1 receptor agonists with demonstrated cardiovascular benefit (e.g., subcutaneous semaglutide, liraglutide, dulaglutide) and/or SGLT2 inhibitors independently of baseline HbA1c to reduce major adverse cardiovascular events (MACE) and cardiovascular mortality.

4Under the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy, what is the initial maintenance pharmacological recommendation for GOLD Group E patients (patients with a history of ≥2 moderate exacerbations or ≥1 exacerbation leading to hospitalization)?

A.Short-Acting Beta-2 Agonist (SABA) monotherapy on an as-needed basis

B.Long-Acting Muscarinic Antagonist (LAMA) combined with a Long-Acting Beta-2 Agonist (LABA)

C.Inhaled Corticosteroid (ICS) monotherapy daily

D.Oral theophylline combined with an oral mucolytic

Explanation: In the GOLD strategy, Group E patients (exacerbation-prone group) should be initiated on dual bronchodilation therapy with LAMA + LABA. If blood eosinophils are ≥300 cells/µL, initial triple therapy (LABA + LAMA + ICS) can be considered, but ICS monotherapy is contraindicated in COPD.

5According to GINA (Global Initiative for Asthma) Track 1 recommendations, what is the preferred reliever and controller regimen across all severity steps in adolescents and adults with asthma?

A.Short-acting beta-2 agonist (SABA) alone as needed without inhaled corticosteroids

B.Low-dose Inhaled Corticosteroid (ICS)–formoterol as needed for symptom relief

C.Oral systemic corticosteroids on alternate days

D.Daily leukotriene receptor antagonist (montelukast) monotherapy

Explanation: GINA Track 1 designates low-dose ICS-formoterol as the preferred reliever across all asthma steps. Using rapid-onset formoterol combined with an inhaled corticosteroid ensures that whenever the patient uses their inhaler for acute bronchospasm relief, they simultaneously receive a micro-dose of anti-inflammatory controller, dramatically reducing severe exacerbations compared to SABA monotherapy.

6A 68-year-old non-valvular atrial fibrillation patient with a CHA2DS2-VASc score of 4 is prescribed rivaroxaban. What is the standard daily maintenance dose in a patient with a creatinine clearance of 65 mL/min, and how should it be taken?

A.10 mg once daily on an empty stomach

B.20 mg once daily taken with the evening meal

C.15 mg twice daily without regard to food

D.5 mg once daily taken in the morning

Explanation: For stroke prevention in non-valvular AF with normal or mildly impaired renal function (CrCl >50 mL/min), the standard dose of rivaroxaban is 20 mg once daily. For the 15 mg and 20 mg tablets, taking the medication with food (such as the main meal) is mandatory because food increases oral bioavailability from ~66% to nearly 100%.

7What is the recommended target LDL-cholesterol level according to ESC/EAS dyslipidemia guidelines for a patient categorized at very high cardiovascular risk (e.g., post-acute coronary syndrome)?

A.LDL-C < 3.0 mmol/L (< 116 mg/dL)

B.LDL-C < 2.6 mmol/L (< 100 mg/dL)

C.LDL-C < 1.4 mmol/L (< 55 mg/dL) and at least a 50% reduction from baseline

D.LDL-C < 1.8 mmol/L (< 70 mg/dL) without requiring percentage reduction

Explanation: For very high-risk cardiovascular patients (such as those with documented ASCVD, post-MI, or diabetes with target organ damage), current ESC/EAS guidelines recommend achieving an LDL-C goal of < 1.4 mmol/L (< 55 mg/dL) alongside a ≥50% reduction from baseline LDL-C levels, typically requiring high-intensity statins combined with ezetimibe.

8Which combination of high-intensity statin regimens achieves an average LDL-C reduction of ≥50% in clinical practice?

A.Atorvastatin 40–80 mg or Rosuvastatin 20–40 mg daily

B.Simvastatin 20 mg or Pravastatin 40 mg daily

C.Lovastatin 20 mg or Fluvastatin 40 mg daily

D.Atorvastatin 10 mg or Rosuvastatin 5 mg daily

Explanation: High-intensity statin therapy is defined by guidelines as therapy that lowers LDL-C on average by ≥50%. The two established high-intensity statin regimens are Atorvastatin 40 to 80 mg daily and Rosuvastatin 20 to 40 mg daily.

9A 55-year-old male with chronic kidney disease (eGFR 38 mL/min/1.73m²) presents with acute gouty arthritis of the first metatarsophalangeal joint. Why are systemic NSAIDs avoided in this patient, and what is the preferred first-line alternative?

A.NSAIDs cause hyperuricemia; allopurinol at 600 mg daily should be initiated immediately

B.NSAIDs impair renal perfusion by inhibiting renal prostaglandins; low-dose colchicine or oral corticosteroids (prednisolone) are preferred

C.NSAIDs trigger acute hepatic necrosis; high-dose aspirin is preferred

D.NSAIDs induce systemic vasodilation; intravenous methotrexate is preferred

Explanation: NSAIDs inhibit cyclooxygenase and block renal vasodilatory prostaglandins (PGE2 and PGI2), which can precipitate acute kidney injury and fluid retention in moderate-to-severe CKD. For acute gout flares in renal impairment, oral corticosteroids (e.g., prednisolone 30–35 mg/day tapered over 5–10 days) or renal-adjusted low-dose colchicine are preferred first-line options.

10In the treatment of Helicobacter pylori infection, what is the rationale behind combining a high-dose Proton Pump Inhibitor (PPI) with antimicrobial agents in quadruple bismuth or non-bismuth regimens?

A.The PPI acts as a direct bactericidal agent against H. pylori cell walls

B.Elevating intragastric pH (pH >6) stabilizes acid-labile antibiotics (e.g., amoxicillin, clarithromycin) and promotes active bacterial replication, increasing antibiotic susceptibility

C.The PPI binds to bacterial flagella to prevent gastric mucosal adhesion

D.The PPI stimulates gastric pepsin secretion to digest the bacterial capsule

Explanation: H. pylori enters a dormant, non-replicative state in highly acidic environments. Suppressing gastric acid production with potent PPI therapy raises intragastric pH above 6, which stabilizes acid-labile antimicrobials (especially amoxicillin and clarithromycin) and stimulates H. pylori into an active replicative state where it becomes susceptible to antibiotic bactericidal action.

About the Albania Pharmacist Certification Exam (Provimi i Certifikimit) Exam

The Albanian Pharmacist Certification Exam (Provimi i Certifikimit) is the statutory catch-up examination taken by pharmacists already in practice who did not meet the continuing-education credit obligation of their certification cycle. It rests on Law No. 10107, dated 30.3.2009 'On Health Care in the Republic of Albania' (as amended) and Council of Ministers Decision No. 789, dated 22.9.2015 on the Certification Programme for Health Professionals (as amended), with the mechanics set by the Certification Exam Regulation issued under Article 33 of Law No. 10107. It is a different assessment from the QSHA state exam (Provimi i Shtetit), which is the entry-to-practice licensing exam for new pharmacy graduates under Law No. 10171 and is covered by a separate question bank. Pharmacists must collect 75 credits across the individual 5-year cycle, with a minimum of 5 per year; a professional who falls short does not have the licence renewed and regains it only by sitting this exam. A pass requires at least 50% of the maximum points. IMPORTANT: the official exam is conducted in Albanian (Shqip), and on the route actually used for pharmacist sittings it is an essay paper of three developed-answer questions, not a multiple-choice test — a 50-item MCQ form is used only when more than 50 candidates register for a specialty. This bank is an English-language multiple-choice study adaptation of the underlying subject matter. It is not an official translation, not a simulation of the official format, and cannot substitute for practising written answers in Albanian.

Assessment

Two routes set by the Certification Exam Regulation, selected by how many professionals register for the specialty. Fewer than 50 registrants: a written exam before the Certification Exam Commission (one Ministry of Health representative, one Professional Order representative and three senior academics, one chairing), held at the premises of the Faculty of Medicine and the 'Nënë Tereza' University Hospital Centre, lasting a maximum of 2 hours, with papers marked within 5 working days. More than 50 registrants: a single computerised round at the National Exam Agency drawn from an open question bank, 60 minutes, starting and finishing simultaneously for all candidates, marked automatically with the result shown on screen and printed for signature. The question bank is grouped into modules by specialty field and graded into three difficulty levels worth 1, 2 and 3 points. Registration is a written request with a copy of the ID card and of the licence to practise, plus the exam payment invoice; UFSH's 2026 notices direct pharmacists to register with ASCK. Candidates bring photo ID and the payment mandate and must arrive at least 30 minutes early; mobile phones are a disqualification ground.

Time Limit

60 minutes for the computerised National Exam Agency route; a maximum of 2 hours for the written exam before the Certification Exam Commission

Passing Score

At least 50% of the maximum points (Article 16 of the Certification Exam Regulation). On the Commission route the paper is marked out of 100 points.

Exam Fee

Set by regulation to be the same as the state exam fee, with the receipts going to the body that runs the sitting (the National Exam Agency, or the continuing-education authority when the Commission runs it). The state-exam tariff under Council of Ministers Decision No. 560, dated 29.9.2018 is 10,000 ALL for a first sitting and rises for repeat attempts. UFSH and ASCK notices do not restate the amount; candidates bring the payment mandate to the sitting. (Ministry of Health and the Continuing Education Board (which issues the certificate on a pass), through either the National Exam Agency or the Certification Exam Commission approved per specialty. Registration and the certification register are administered by ASCK (formerly QKEV); Urdhri i Farmacistëve të Shqipërisë (UFSH) is co-responsible for drafting the exam programme and publishes the sitting notices.)

Albania Pharmacist Certification Exam (Provimi i Certifikimit) Exam Content Outline

Not published

Clinical Pharmacotherapy & Chronic Disease Management

Updated evidence-based therapeutic management of cardiovascular diseases (hypertension, heart failure, ACS), metabolic disorders (diabetes mellitus, dyslipidemia), respiratory conditions (asthma, COPD), antimicrobial stewardship, and central nervous system disorders.

Not published

Pharmacovigilance, Adverse Drug Reactions & Patient Safety

Detection, evaluation, and official reporting of adverse drug reactions (ADRs) to the National Agency for Drugs and Medical Devices (AKBPM), black triangle monitoring, causality assessment, medication error prevention, and post-marketing safety alerts.

Not published

Drug-Drug Interactions, CYP450 Metabolism & Toxicology

Pharmacokinetic and pharmacodynamic interactions involving CYP450 isozymes, P-glycoprotein, QT-prolonging drugs, narrow therapeutic index drug monitoring (digoxin, lithium, warfarin, theophylline, aminoglycosides), acute poisoning mechanisms, and specific antidotes.

Not published

Albanian Pharmaceutical Legislation, Deontology & Reimbursed Drug Systems

Regulatory framework governing pharmaceutical practice in Albania, including Law No. 105/2014, Law No. 10107, VKM No. 789, UFSH Code of Ethics and Deontology, prescription categories (OTC, POM, special narcotics/psychotropics prescriptions), and FSDKSH reimbursement drug list procedures.

Not published

Good Pharmacy Practice, Storage, Cold Chain & Compounding

Good Pharmacy Practice (GPP) and Good Storage Practice (GSP) standards, cold-chain temperature maintenance (2°C–8°C) and excursion protocols, pharmaceutical waste management and expired medicine disposal, extemporaneous compounding quality assurance, and beyond-use dates (BUD).

Not published

Special Populations, Patient Counseling & OTC Management

Safe pharmacotherapy in special populations (pregnancy, lactation, pediatrics, and geriatrics including Beers criteria), renal and hepatic dose adjustments, over-the-counter (OTC) consultations, patient adherence counseling, and public health promotion.

How to Pass the Albania Pharmacist Certification Exam (Provimi i Certifikimit) Exam

What You Need to Know

Passing score: At least 50% of the maximum points (Article 16 of the Certification Exam Regulation). On the Commission route the paper is marked out of 100 points.
Assessment: Two routes set by the Certification Exam Regulation, selected by how many professionals register for the specialty. Fewer than 50 registrants: a written exam before the Certification Exam Commission (one Ministry of Health representative, one Professional Order representative and three senior academics, one chairing), held at the premises of the Faculty of Medicine and the 'Nënë Tereza' University Hospital Centre, lasting a maximum of 2 hours, with papers marked within 5 working days. More than 50 registrants: a single computerised round at the National Exam Agency drawn from an open question bank, 60 minutes, starting and finishing simultaneously for all candidates, marked automatically with the result shown on screen and printed for signature. The question bank is grouped into modules by specialty field and graded into three difficulty levels worth 1, 2 and 3 points. Registration is a written request with a copy of the ID card and of the licence to practise, plus the exam payment invoice; UFSH's 2026 notices direct pharmacists to register with ASCK. Candidates bring photo ID and the payment mandate and must arrive at least 30 minutes early; mobile phones are a disqualification ground.
Time limit: 60 minutes for the computerised National Exam Agency route; a maximum of 2 hours for the written exam before the Certification Exam Commission
Exam fee: Set by regulation to be the same as the state exam fee, with the receipts going to the body that runs the sitting (the National Exam Agency, or the continuing-education authority when the Commission runs it). The state-exam tariff under Council of Ministers Decision No. 560, dated 29.9.2018 is 10,000 ALL for a first sitting and rises for repeat attempts. UFSH and ASCK notices do not restate the amount; candidates bring the payment mandate to the sitting.

Keys to Passing

Work through all 100 available questions
Review every answer and explanation
Track weak areas and revisit them
Use our AI tutor for tough concepts

Frequently Asked Questions

How does the Pharmacist Certification Exam differ from the State Exam (Provimi i Shtetit)?

The State Exam (Provimi i Shtetit) is governed by Law No. 10171 and organized by QSHA as the entry-to-practice licensing exam for new pharmacy graduates. In contrast, the Certification Exam (Provimi i Certifikimit) is governed by Law No. 10107 and VKM No. 789/2015, organized by UFSH and ASCK specifically for practicing pharmacists who did not complete their required 75 continuing education credits during their 5-year cycle.

Who is required to sit for the Provimi i Certifikimit?

Licensed pharmacists in Albania who, at the conclusion of their 5-year certification cycle under the Continuing Professional Development (CPD) program, failed to accumulate the minimum 75 continuing education credits (with at least 5 credits per year) must sit for the certification examination to renew their certification standing.

What is the format of the exam, how long does it last, and what is the pass mark?

The Certification Exam Regulation sets two routes by registration volume. If fewer than 50 professionals register for a specialty, the Certification Exam Commission runs a written paper of three developed-answer (essay) questions marked out of 100 points, lasting a maximum of 2 hours; at least seven papers are prepared in advance and marking is completed within 5 working days. If more than 50 register, the National Exam Agency runs a computerised test of 50 multiple-choice items, each with at least four options and one correct answer, lasting 60 minutes in a single round with automatic marking. Either way, a pass requires at least 50% of the maximum points. Pharmacist sittings announced by UFSH take place at the Faculty of Medicine, which is the Commission route venue.

Where and when is the examination administered?

Dates are set by the Ministry of Health and announced by UFSH and ASCK. Recent pharmacist sittings were held on 11 February 2026, 11 May 2026 and 30 June 2026, following 10 July 2025 and 28 February 2025. The 30 June 2026 sitting began at 10:00 at the premises of the Faculty of Medicine in Tirana; the regulation names the Faculty of Medicine and the 'Nënë Tereza' University Hospital Centre as the venues for the Commission route.

What documentation is required to register for the certification exam?

A written request to register, a photocopy of the national identification card, and a photocopy of the licence to practise (leja e ushtrimit të profesionit). The regulation also lists the exam payment invoice among the attachments. UFSH's 2026 notices direct pharmacists to register with ASCK, which absorbed the continuing-education centre's functions. On the day, candidates bring photo ID and the payment mandate and must arrive at least 30 minutes before the start; mobile phones are a ground for disqualification.

Is any pharmacist exempt from having to sit the certification exam?

Yes. The regulation exempts three groups: a professional employed in the public health service who reaches pension age within 2 years or less; a professional who received the licence to practise for the first time within 2 years before the end of the certification cycle; and a professional who has turned 75 by the date the certification cycle ends.

What happens if a practicing pharmacist does not fulfill the certification cycle requirements?

According to UFSH, a health professional who does not meet the certification programme criteria has their contract with the health institution suspended or terminated and the licence to practise is not renewed by the professional order. The licence is regained only after the professional sits the certification exam, which is precisely why this exam exists. On passing, the Continuing Education Board issues the certificate, which is lodged with the professional order.

What are the continuing education credit requirements for Albanian pharmacists?

According to ASCK guidelines under VKM No. 789/2015, pharmacists must achieve at least 75 accredited continuing education credits across each 5-year cycle, with a mandatory minimum of 5 credits earned in each calendar year.